Kivu Bioscience has closed a $92 million series A financing to advance its topoisomerase I inhibitor-based antibody-drug conjugate (ADC) pipeline into the clinic.
Researchers at the Stony Brook University Renaissance School of Medicine performed a screening in search of Kruppel-like factor 15 (KLF15) agonists for treating proteinuric injuries in the kidney.
Researchers from Zymeworks Inc. presented preclinical data for the novel glypican-3 (GPC3)-targeting antibody-drug conjugate (ADC), ZW-251, being developed as an anticancer agent.
Dewpoint Therapeutics Inc. has nominated its first development candidate, DPTX-3186, an orally administered small-molecule condensate modulator inhibiting the oncogenic function of β-catenin, for the treatment of Wnt-driven cancers.
Genome & Co. Ltd. has reported preclinical findings of its anti-CNTN4 antibody, GENA-104A16, and anti-APP antibody, 5A7 — stressing the contactin-4 (CNTN4) and amyloid precursor protein (APP) axis as a potential target for immuno-oncology. In the latest murine experiments, investigators led by Genome executives and researchers of Gwangju Institute of Science and Technology (GIST) found that blocking the interaction between CNTN4 and APP promoted cancer-destroying responses in mice, suggesting the pathway as a target for immunotherapy.
Bivision Biomedical Technology (Nanjing) Co. Ltd. has described radiolabeled-metal complexes targeting fibroblast activation protein α (FAP) reported to be useful for the diagnosis and treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Suzhou Ansailong Pharmaceutical Technology Co Ltd. has identified mitochondrial ATP-dependent Clp protease proteolytic subunit (ClpP) activators reported to be useful for the treatment of cancer, AIDS, nonalcoholic fatty liver disease (metabolic dysfunction-associated steatotic liver disease [MASLD]) and neurological disorders.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Immunome Inc. and Zentalis Pharmaceuticals Inc. presented preclinical data for IM-1021, a novel tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate with a new topoisomerase 1 (TOP1) linker payload, being developed for the treatment of solid tumors and B-cell malignancies.
RSS
